Evaluation of single anastomosis sleeve ileal bypass in the treatment of morbidly obese patients with type 2 diabetes mellitus | ||
| The Egyptian Journal of Surgery | ||
| Volume 43, Issue 4, October 2024, Pages 1139-1145 PDF (429.85 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/EJSUR.2024.276377.1022 | ||
| Authors | ||
| Aliaa Selim* ; Hany El-Hadad; Abdel-Hamid Ghazal; Magdy Akel | ||
| Department of General Surgery, Faculty of Medicine, University of Alexandria, Alexandria, Egypt | ||
| Abstract | ||
| Background: Laparoscopic single anastomosis sleeve ileal (SASI) bypass has recently evolved as a novel approach to treating both obesity and its associated comorbidities. This study aims to evaluate the efficacy and feasibility of SASI bypass in patients with obesity and type 2 diabetes mellitus (T2DM). Patients and Methods: We conducted a prospective study on 30 morbidly obese patients having T2DM between January 2021 to September 2022. All the patients underwent laparoscopic SASI bypass, and all were followed for 12 months after surgery in terms of T2DM remission. Other parameters were also recorded and analyzed. The percentage of mean excess weight loss (EWL%) was evaluated and noted at each follow-up. Results: At 12 months, EWL% was 82%. All the patients evaluated had shown T2DM remission by 1 year (6.7% partial remission and 93.3% complete remission), with 77.8% remission of hypertension and 95.5% remission of dyslipidemia. Conclusion: SASI offers an excellent EWL% reduction, T2DM remission, and comorbidities resolution, and it should be considered an effective way to treat obesity in T2DM. | ||
| Keywords | ||
| Bariatric surgery; laparoscopic single anastomosis sleeve ileal bypass; metabolic surgery | ||
|
Statistics Article View: 82 PDF Download: 131 |
||
